IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Middleton & Co. Inc. MA

Key Points

• Middleton & Co. Inc. reduced its stake in IQVIA Holdings Inc. by 4.8%, holding shares worth approximately $8.13 million at the end of the last quarter.
• In the latest quarterly earnings, IQVIA reported $2.81 EPS, exceeding analyst expectations, with revenues of $4.02 billion which is a 5.3% increase from the previous year.
• Currently, the majority of IQVIA's stock, approximately 89.62%, is owned by institutional investors and hedge funds, indicating strong institutional interest in the company.

Middleton & Co. Inc. MA lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,122 shares of the medical research company's stock after selling 2,316 shares during the period. Middleton & Co. Inc. MA's holdings in IQVIA were worth $8,131,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of IQV. Brighton Jones LLC lifted its position in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after purchasing an additional 2,537 shares during the period. Wellington Management Group LLP lifted its position in IQVIA by 12.7% during the fourth quarter. Wellington Management Group LLP now owns 9,791 shares of the medical research company's stock valued at $1,924,000 after acquiring an additional 1,106 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in IQVIA by 5.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 142,249 shares of the medical research company's stock valued at $27,953,000 after acquiring an additional 7,546 shares during the last quarter. Resona Asset Management Co. Ltd. purchased a new stake in IQVIA during the fourth quarter valued at approximately $10,840,000. Finally, Russell Investments Group Ltd. lifted its position in IQVIA by 9.4% during the fourth quarter. Russell Investments Group Ltd. now owns 129,841 shares of the medical research company's stock valued at $25,548,000 after acquiring an additional 11,119 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. Barclays upped their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their price target for the company from $260.00 to $160.00 in a research note on Friday, April 25th. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group upped their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, Redburn Partners set a $188.00 price objective on shares of IQVIA in a research note on Friday, May 23rd. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $228.62.

IQVIA Stock Up 0.8%

NYSE IQV traded up $1.50 on Thursday, hitting $178.99. 1,028,825 shares of the stock were exchanged, compared to its average volume of 2,429,466. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a market cap of $30.43 billion, a PE ratio of 25.90, a PEG ratio of 1.95 and a beta of 1.30. The company has a 50-day moving average price of $164.68 and a 200-day moving average price of $169.75.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the prior year, the business posted $2.64 EPS. The company's revenue for the quarter was up 5.3% on a year-over-year basis. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.